Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma - Summary - MDSpire

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma

  • By

  • Frida Bugge Askeland

  • Vilhelm Hauge Bugge

  • Anne-Marie Rasmussen

  • Anna Lysén

  • Einar Haukås

  • Magnus Moksnes

  • Anette L. Eilertsen

  • Galina Tsykunova

  • Birgitte Dahl Eiken

  • Nils Morten Leknes

  • Jürgen Rolke

  • Vidar Stavseth

  • Eivind Samstad

  • Randi Fykse Hallstensen

  • Damian Szatkowski

  • Ariane Aasbø Hansen

  • Anita Smith Nilsen

  • Tobias S. Slørdahl

  • Pegah Abdollahi

  • Fredrik Schjesvold

  • December 22, 2025

  • 0 min

Share

Objective:

To evaluate the safety, renal response, and overall response rate of higher-dose lenalidomide in transplant-eligible newly diagnosed multiple myeloma patients with renal impairment, focusing on specific safety outcomes related to renal function.

Key Findings:
  • Renal impairment significantly reduces overall survival in multiple myeloma patients, highlighting the need for effective treatment strategies.
  • Rapid renal recovery is associated with improved clinical outcomes, reinforcing the importance of timely intervention.
  • Higher doses of lenalidomide may be tolerated in patients with renal impairment, potentially leading to faster serum-free light chain reduction and better overall prognosis.
Interpretation:

The findings suggest that lenalidomide dosing may be optimized in patients with renal impairment, challenging current conservative dosing recommendations and potentially influencing future treatment guidelines.

Limitations:
  • The study is ongoing, and results are preliminary, which may limit the applicability of findings until the study is completed.
  • The trial's design may limit generalizability to all multiple myeloma patients with renal impairment, particularly those outside the study's inclusion criteria.
Conclusion:

Higher-than-label doses of lenalidomide could be safely administered in TE-NDMM patients with renal impairment, potentially improving treatment outcomes.

Original Source(s)

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma

  • by Frida Bugge Askeland, Vilhelm Hauge Bugge, Anne-Marie Rasmussen, Anna Lysén, Einar Haukås, Magnus Moksnes, Anette L. Eilertsen, Galina Tsykunova, Birgitte Dahl Eiken, Nils Morten Leknes, Jürgen Rolke, Vidar Stavseth, Eivind Samstad, Randi Fykse Hallstensen, Damian Szatkowski, Ariane Aasbø Hansen, Anita Smith Nilsen, Tobias S. Slørdahl, Pegah Abdollahi, Fredrik Schjesvold

  • December 22, 2025

Related Content

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence